Literature DB >> 23432647

Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail.

Adam M Fontebasso1, Xiao-Yang Liu, Dominik Sturm, Nada Jabado.   

Abstract

Primary brain tumors occur in 8 out of 100 000 people and are the leading cause of cancer-related death in children. Among brain tumors, high-grade astrocytomas (HGAs) including glioblastoma multiforme (GBM) are aggressive and are lethal human cancers. Despite decades of concerted therapeutic efforts, HGAs remain essentially incurable in adults and children. Recent discoveries have revolutionized our understanding of these tumors in children and young adults. Recurrent somatic driver mutations in the tail of histone 3 variant 3 (H3.3), leading to amino acid substitutions at key residues, namely lysine (K) 27 (K27M) and glycine 34 (G34R/G34V), were identified as a new molecular mechanism in pediatric GBM. These mutations represent the pediatric counterpart of the recurrent mutations in isocitrate dehydrogenases (IDH) identified in young adult gliomas and provide a much-needed new pathway that can be targeted for therapeutic development. This review will provide an overview of the potential role of these mutations in altering chromatin structure and affecting specific molecular pathways ultimately leading to gliomagenesis. The distinct changes in chromatin structure and the specific downstream events induced by each mutation need characterizing independently if progress is to be made in tackling this devastating cancer.
© 2013 The Authors; Brain Pathology © 2013 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23432647     DOI: 10.1111/bpa.12023

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  41 in total

Review 1.  Epigenetics components of aging in the central nervous system.

Authors:  Yue-Qiang Zhao; I King Jordan; Victoria V Lunyak
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

2.  Identification of recurrent SMO and BRAF mutations in ameloblastomas.

Authors:  Robert T Sweeney; Andrew C McClary; Benjamin R Myers; Jewison Biscocho; Lila Neahring; Kevin A Kwei; Kunbin Qu; Xue Gong; Tony Ng; Carol D Jones; Sushama Varma; Justin I Odegaard; Toshihiro Sugiyama; Souichi Koyota; Brian P Rubin; Megan L Troxell; Robert J Pelham; James L Zehnder; Philip A Beachy; Jonathan R Pollack; Robert B West
Journal:  Nat Genet       Date:  2014-05-25       Impact factor: 38.330

3.  Management of high-grade gliomas in the pediatric patient: Past, present, and future.

Authors:  Magimairajan Issai Vanan; David D Eisenstat
Journal:  Neurooncol Pract       Date:  2014-09-12

4.  H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.

Authors:  Alok Mohan Uppar; Harsha Sugur; A R Prabhuraj; M Bhaskara Rao; B Indira Devi; S Sampath; A Arivazhagan; Vani Santosh
Journal:  Childs Nerv Syst       Date:  2019-05-31       Impact factor: 1.475

Review 5.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

6.  Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.

Authors:  Li Liang; Adriana Olar; Na Niu; Yi Jiang; Wenjun Cheng; Xiu-Wu Bian; Wentao Yang; Jing Zhang; Anna Yemelyanova; Anais Malpica; Zhihong Zhang; Gregory N Fuller; Jinsong Liu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

7.  Diffuse Midline Glioma H3 K27M-Mutant Manifested as Progressive Paraplegia.

Authors:  Eric D Goldstein; Christopher M Kyper; Jason L Siegel
Journal:  Neurohospitalist       Date:  2019-05-07

Review 8.  Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.

Authors:  Daniel R Principe; Suneel D Kamath; Hidayatullah G Munshi; Nisha A Mohindra
Journal:  Oncologist       Date:  2019-11-01

9.  H3F3A K27M mutations in thalamic gliomas from young adult patients.

Authors:  Koki Aihara; Akitake Mukasa; Kengo Gotoh; Kuniaki Saito; Genta Nagae; Shingo Tsuji; Kenji Tatsuno; Shogo Yamamoto; Shunsaku Takayanagi; Yoshitaka Narita; Soichiro Shibui; Hiroyuki Aburatani; Nobuhito Saito
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

10.  Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.

Authors:  M S Aboian; D A Solomon; E Felton; M C Mabray; J E Villanueva-Meyer; S Mueller; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2017-02-09       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.